Becton Dickinson and Co. (NYSE:BDX) shares reached a new 52-week high on Monday . The stock traded as high as $177.85 and last traded at $176.79, with a volume of 393,913 shares changing hands. The stock had previously closed at $175.47.

A number of research analysts have issued reports on BDX shares. Bank of America Corp. restated a “buy” rating on shares of Becton Dickinson and in a research report on Thursday, May 12th. Zacks Investment Research upgraded shares of Becton Dickinson and from a “hold” rating to a “buy” rating and set a $180.00 target price on the stock in a research report on Wednesday, May 4th. JPMorgan Chase & Co. restated a “buy” rating on shares of Becton Dickinson and in a research report on Tuesday, May 3rd. Argus restated a “buy” rating on shares of Becton Dickinson and in a research report on Sunday, June 12th. Finally, Jefferies Group increased their target price on shares of Becton Dickinson and from $190.00 to $192.00 and gave the stock a “buy” rating in a research report on Thursday, July 28th. Eight analysts have rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the company. Becton Dickinson and presently has an average rating of “Buy” and an average price target of $169.46.

The firm’s 50 day moving average price is $174.81 and its 200 day moving average price is $163.55. The company has a market cap of $37.84 billion and a PE ratio of 33.92.

Becton Dickinson and (NYSE:BDX) last announced its quarterly earnings data on Thursday, August 4th. The company reported $2.35 EPS for the quarter, topping the consensus estimate of $2.21 by $0.14. The company earned $3.20 billion during the quarter, compared to the consensus estimate of $3.21 billion. The business’s revenue was up 2.5% on a year-over-year basis. During the same period in the prior year, the firm posted $2.05 EPS. Equities research analysts expect that Becton Dickinson and Co. will post $8.57 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, September 30th. Stockholders of record on Friday, September 9th will be given a $0.66 dividend. This represents a $2.64 annualized dividend and a dividend yield of 1.49%. The ex-dividend date is Wednesday, September 7th.

In other news, EVP Nabil Shabshab sold 5,080 shares of the business’s stock in a transaction that occurred on Tuesday, June 7th. The shares were sold at an average price of $168.75, for a total value of $857,250.00. Following the sale, the executive vice president now owns 11,092 shares of the company’s stock, valued at $1,871,775. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Gary M. Cohen sold 29,367 shares of the business’s stock in a transaction that occurred on Thursday, August 11th. The shares were sold at an average price of $176.81, for a total transaction of $5,192,379.27. Following the completion of the sale, the insider now directly owns 125,870 shares in the company, valued at approximately $22,255,074.70. The disclosure for this sale can be found here.

Several hedge funds have bought and sold shares of the stock. American International Group Inc. raised its stake in Becton Dickinson and by 2.7% in the fourth quarter. American International Group Inc. now owns 81,525 shares of the company’s stock valued at $12,563,000 after buying an additional 2,121 shares during the period. Schwab Charles Investment Management Inc. raised its stake in Becton Dickinson and by 2.7% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 585,304 shares of the company’s stock valued at $90,190,000 after buying an additional 15,361 shares during the period. Finally, Dimensional Fund Advisors LP raised its stake in Becton Dickinson and by 3.4% in the fourth quarter. Dimensional Fund Advisors LP now owns 348,912 shares of the company’s stock valued at $53,767,000 after buying an additional 11,489 shares during the period.

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical devices, instrument systems and reagents used by healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.